Jerome Korten

Retia Medical LLC is a digital health company that develops advanced hemodynamic solutions for high-risk patients. The company is based in Valhalla, NY, and was founded by Marc Zemel and Ramakrishna Mukkamala. The company's proprietary technology, the Argos Cardiac Output (CO) monitor, provides consistently accurate hemodynamic measurements by analyzing multiple heartbeats (MBA™) and not just a single beat at a time. The Argos CO monitor eliminates the need for costly disposables to monitor each patient and is available at a low, fixed-capital cost. Marc Zemel has been the CEO since incorporation.

Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ.

Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ.

Onebreath, Inc. operates as a medical device firm. it develops a ventilator that provides continuous respiratory support for infant through adult patients. The company was founded by Vijayasimha Ajarananda, Bryan E. Loomas, and Matthew John Callaghan and is headquartered in Palo Alto, CA.

Onebreath, Inc. operates as a medical device firm. it develops a ventilator that provides continuous respiratory support for infant through adult patients. The company was founded by Vijayasimha Ajarananda, Bryan E. Loomas, and Matthew John Callaghan and is headquartered in Palo Alto, CA.

Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ.

Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ.

Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ.